Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Nov
05
Today In Oncology
16 Million PRISM Trial Will Explore AI in Breast Cancer Screening
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Study Finds Breast Cancer Risk Varies Between Different Hormonal Contraceptives
Diminishing the National Cancer Institute Threatens Americans
Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo